OncoSec Medical Incorporated (ONCS) Trading Up 4%
OncoSec Medical Incorporated (NASDAQ:ONCS)’s share price was up 4% during trading on Thursday . The stock traded as high as $2.55 and last traded at $2.08. Approximately 6,211,052 shares traded hands during trading, an increase of 157% from the average daily volume of 2,416,182 shares. The stock had previously closed at $2.00.
Several equities analysts have recently commented on ONCS shares. ValuEngine upgraded shares of OncoSec Medical from a “strong sell” rating to a “sell” rating in a research report on Friday, July 14th. Maxim Group restated a “buy” rating and set a $5.00 price target on shares of OncoSec Medical in a research report on Friday, September 1st. Finally, HC Wainwright restated a “buy” rating and set a $6.00 price target on shares of OncoSec Medical in a research report on Thursday. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the stock. OncoSec Medical currently has an average rating of “Buy” and an average target price of $5.33.
OncoSec Medical (NASDAQ:ONCS) last announced its earnings results on Wednesday, October 25th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.05).
OncoSec Medical Company Profile
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.
Receive News & Ratings for OncoSec Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.